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Abstract
Cell surface β-Amyloid precursor protein (APP) is known to have a functional role in iron homeostasis through stabilising 
the iron export protein ferroportin (FPN). Mechanistic evidence of this role has previously only been provided through 
transcriptional or translational depletion of total APP levels. However, numerous post-translational modifications of APP 
are reported to regulate the location and trafficking of this protein to the cell surface. Stable overexpressing cell lines were 
generated that overexpressed APP with disrupted N-glycosylation  (APPN467K and  APPN496K) or ectodomain phosphoryla-
tion  (APPS206A); sites selected for their proximity to the FPN binding site on the E2 domain of APP. We hypothesise that 
impaired N-glycosylation or phosphorylation of APP disrupts the functional location on the cell surface or binding to FPN to 
consequentially alter intracellular iron levels through impaired cell surface FPN stability. Outcomes confirm that these post-
translational modifications are essential for the correct location of APP on the cell surface and highlight a novel mechanism by 
which the cell can modulate iron homeostasis. Further interrogation of other post-translational processes to APP is warranted 
in order to fully understand how each modification plays a role on regulating intracellular iron levels in health and disease.
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Introduction
β-Amyloid precursor protein (APP) is a type 1 transmem-
brane glycoprotein with a sequence that is highly conserved 
in the vertebrate phyla, suggesting an important physiologi-
cal role [1, 2]. In humans it exists as several different length 
isoforms, with the shortest containing 695 residues being the 
predominant neuronal isoform [3, 4]. The greatest research 
attention on this protein has been its association with Alz-
heimer’s disease (AD). As the name suggests APP is the 
precursor to amyloid-β (Aβ), the peptide prominently pre-
sent within senile plaques, and familial mutations in the APP 
gene elevate the production of Aβ in early onset AD. Func-
tionally it has been implicated in a multitude of roles ranging 
from signalling to cell adhesion [5]. However, more recently 
a role in neuronal iron homeostasis has also been proposed, 
whereby cell surface APP can stabilise the iron export pro-
tein ferroportin (FPN), to enable cellular iron efflux through 
this pore protein [6–10]. All prior evidence of this iron regu-
latory role in APP has come from reports in which total APP 
has been ablated by transcriptional knockout or translational 
knockdown. However, APP is known to have numerous post-
translational modifications (PTMs) that regulate location 
and trafficking throughout the cell. Most heavily researched 
are the proteolytic processing pathways of APP, largely due 
to Aβ being a product from the amyloidogenic cleavage of 
APP. However, before APP reaches the cell surface and is 
predominantly directed down these processing pathways, a 
series of other PTMs are required for its transport from the 
endoplasmic reticulum (ER) to the cell surface. As APP is 
considered to have a main functional location on the cell 
surface, trafficking to this location is a key regulator in the 
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function of the full length protein as well as the downstream 
production of cleavage products such as Aβ.
Broadly, APP is synthesised in the ER and transported 
to the Golgi, where it enters the trans-Golgi network (TGN) 
before it is trafficked to and from the cell surface through 
several cellular compartments. How long APP is held in each 
compartment can thus determine the proportion of APP that 
is present on the cell surface and have a regulatory control 
in the function of APP, such as binding and stabilising FPN 
in the case of iron efflux. During trafficking of APP a wide 
range of PTMs extensively alter cellular localisation and 
their ablation can prevent APP from moving between com-
partments (for review see [11]). The effects of glycosylation 
and phosphorylation have been the focus of most investiga-
tion in this area, but APP is also known to be palmitoylated, 
ubiquitinated, sumoylated and sulphated. Several of these 
modifications may have a close interplay as has been shown 
with other transmembrane proteins [12, 13]. Unglycosylated 
APP is referred to as immature as only glycosylated APP is 
present on the cell surface and subsequently secreted [14, 
15]. APP can undergo both N- and O-linked glycosylation. 
N-glycosylation of APP originates in the ER, from which it 
is relocated to the Golgi/TGN, where an O-glycosylation is 
added along with a number of other PTM’s (e.g. sulfation, 
palmitolyation and phosphorylation) [16]. N-glycosylation 
occurs at two asparagine residues within the E2 domain of 
APP; N467 and N496 on  APP695 [17] and is essential for 
APP trafficking [15, 18–20]. The fully glycosylated APP 
has a preference to also be phosphorylated with several sites 
in both the extracellular and cytoplasmic domains. While 
more studies about APP phosphorylation have focused on 
residues within the cytoplasmic domain, two serine resi-
dues in the ectodomain are also phosphorylated under basal 
conditions. Intracellular phosphorylation of serine 196 and 
206 on  APP695 (S196 and S206) are both necessary for APP 
trafficking [21] but can also be phosphorylated on the cell 
membrane, indicating a function distinct from trafficking 
[22].
To explore whether PTMs of APP were able to alter the 
normal functional role of cell surface APP in iron homeo-
stasis, we focused on modifying N-glycosylation and ecto-
domain phosphorylation sites located near the previously 
identified FPN binding sequence in the E2 domain of APP 
(amino acids 327–348 on  APP695) [6]. We hypothesised that 
impaired N-glycosylation and phosphorylation at these sites 
would either disrupt location of APP on the cell surface or 
binding of APP to FPN and have a consequential effect of 
intracellular iron levels through impaired cell surface FPN 
stability. Neuroblastomas stably overexpressing either wild-
type  APP695 or where the N-glycosylation sites or S206 
phosphorylation site were mutated were investigated for 
cellular location of APP and FPN as well as intracellular 
iron levels.
Methods
Generation and Maintenance of Stable APP 
Cell‑Lines
N2a neuroblastoma cell-lines were maintained in DMEM 
media (Lonza) containing 10% fetal bovine serum at 37 °C 
and 5%  CO2. The phosphorylation (S206A) and N-glyco-
sylation (N467K and N496K) mutations in  APP695 were 
generated through PCR-derived mutagenesis of wild-
type-APP695 in pIREShyg (BD Biosciences) using the 
QuikChange II XL Site-Directed Mutagenesis Kit (Agi-
lent Technologies). Ablation of the phosphorylation site at 
S206 was carried out by designing primers that substituted 
nucleotide T–G at position 616, ablation of the gylcosylation 
site at N467 was by substituting nucleotide T–G at posi-
tion 1401 and ablation of the gylcosylation site at N496 
was by substituting nucleotide C–G at position 1488. Both 
protein and DNA sequences are in reference to the 695 iso-
form sequence. Transiently transfected cells were checked 
for viability before stable transfected N2a neuroblastoma 
cell-lines for wild-type-APP695  (APPWT), the APP mutants 
 (APPS206A,  APPN467K and  APP496K) and pIREShyg empty 
vector were generated by electroporation (250V; 1650 µF). 
In the presence of hygromycin B (250 µg/mL), 30 µg of plas-
mid was used to transfect cells within a 75 cm2 flask. After 
24 h media was replaced with DMEM + 10% FBS and cells 
were allowed to grow to 80% confluency. At this point selec-
tion of successfully transfected cells were maintained by 
the addition of hygromycin B to the media (DMEM + 10% 
FBS containing hygromycin B, 250 µg/mL). Clones for each 
stably incorporated transgene were selected based on com-
parable expression levels to clones of the other constructs.
Antibodies
For APP, recognition of N-terminal epitopes was with 
22C11 (1:50, Millipore UK Ltd, Livingston, UK) or 
AB15272 (1:50; Abcam, Cambridge, UK) whereas sAPPβ 
was detected with 1A9 (1:2500; provided by I. Hussain, 
Glaxo- SmithKline, Harlow, UK) [23]. Protein response 
to iron was detected with rabbit anti-Ferritin (1:1000, Cell 
Signalling Technology). Ferroportin location was identified 
using rabbit anti-FPN (1:50; BioScience Life Sciences). 
Loading control was established with mouse anti-β-actin 
(1:5000, AC15, Sigma). The fluorescently labeled second-
ary antibodies Alexa Fluor 488 Goat anti-Rabbit IgG and 
Alexa Fluor 488 Goat anti-Mouse IgG were from Molecular 




After each experimental condition media was collected and 
concentrated using Microcon-30 kDa condensers (Milli-
pore; 30 kDa cut off), while cells were washed twice with 
cold PBS before collection and homogenised in RIPA buffer 
(150 mM NaCl, 1% (v/v) Nonidet P-40, 1% (w/v) sodium 
deoxycholate, 0.1% (v/v) SDS, 25 mM Tris–HCl, pH 7.6) 
with EDTA-free protease inhibitor cocktail (Complete; 
Roche). Lysates were clarified by centrifugation at 14,000×g 
for 15 min.
As determined by BCA assay, 10 µg total protein in 
media or cell lysate from each experimental condition was 
separated either on 10% PAGE (Tris–Glycine, BioRad) for 
detection of sAPP/APP (22C11 or 1A9) and 4–20% PAGE 
(Tris–Glycine, BioRad) for FT. Resolved proteins trans-
ferred to polyvinylidene difluoride membranes (Hybond-P, 
GE Healthcare Life Sciences) were probed with primary 
and secondary antibodies before visualization with ECL 
(ThermoScientific) using a LAS-3000 Imaging suite. Den-
sitometry using Image J (NIH) was performed in triplicate 
on three separate experiments unless otherwise stated and all 
quantitation was standardized against β-actin levels.
Fluorescence‑Activating Cell Sorting (FACS) Analysis
Neuroblastoma lines were lightly-fixed (1% paraformal-
dehyde) and assayed by flow cytometry (FACS) for cell-
surface bound APP and FPN. Antibodies raised against the 
extracellular domain epitope for APP (AB15272) or FPN 
were used. Cells were sorted by forward and side scatter 
on a BD-LSR-Fortessa (BD Biosciences) according to fluo-
rescence at 530 ± 30 nM. Upon gating to ensure only a live 
cell population was monitored, a minimum of 10,000 cells 
were recorded in each experiment, duplicated and repeated 
in three separate experiments. Data were analyzed using BD 
FACS DiVa 6 and FlowJo 7.6.4 software.
Analysis of Labile Iron Pool
The cytoplasmic labile iron pool of all stable cell-lines were 
measured by a Calcein-AM assay adapted from a previ-
ously reported procedure [24]. Briefly, cells were plated at 
20,000 cells/well in a black 96-well microplate before treat-
ment with each experimental condition. Cells were washed 
twice with PBS after which Calcein-AM (60 nM) was added. 
Fluorescence at an excitation of 485 nm and emission of 
535 nm measurements were started immediately and taken 
every minute using a Biotek Fluorescence microplate reader 
for 10 min or until a consistent minimum reading had been 
reached. In triplicate, deferiprone was rapidly added and 
fluorescence measurements started again immediately. Read-
ings were continued for a further 5 min or until a plateau had 
been reached. The percentage labile iron pool chelated was 
calculated as the ΔF (the difference in fluorescence from 
before and after chelator addition) for each condition com-
pared to the  APPWT overexpressing control under endog-
enous iron homeostatic regulation.
Results
APP Mutants Reduce Trafficking to the Cell Surface 
Reducing APP Degradation
Colonies from single stably transfected N2a neuroblasto-
mas were selected for empty vector control (Hyg),  APPWT 
and mutations lacking an extracellular phosphorylation 
 (APPS206A) or N-glycosylation  (APPN467K and  APPN496K) 
site (Fig. 1a). Colonies were selected based on APP expres-
sion in the cell, as determined by mRNA (data not shown) 
and total protein expression (Fig. 1b), only being increased 
by ~ 50% compared to endogenous APP in N2a (as shown by 
Hyg in Fig. 1b). Upon comparing the wild-type APP levels, 
it was shown that deletion of either the phosphorylation or 
N-glycosylation sites increased total cellular full-length APP 
levels (Fig. 1b).
APP is proposed to have its main functional role as a type 
1 transmembrane protein on the cell surface. To interrogate 
the effect of these mutations on cellular location of APP, we 
further investigated cell surface levels (Fig. 1c), as well as 
the processing of APP through its downstream proteolytic 
pathways (Fig. 1d). Of the total APP in the cell, only a small 
fraction is known to localise to the cell surface. Despite only 
a small increase in total APP above endogenous levels in the 
 APPWT cell line, a ~ sixfold increase in the cell surface levels 
of  APPWT was measured by flow cytometry. Intriguingly, 
despite a retention of total levels of APP in the cell when the 
extracellular phosphorylation  (APPS206A) or N-glycosylation 
 (APPN467K and  APPN496K) site mutations were introduced 
into APP, the level of APP on the cell surface in all three 
cell lines was significantly reduced compared to  APPWT 
(Fig. 1c).
The lack of APP on the cell surface caused by the intro-
duction of these PTM mutations could be through two 
mechanisms; either the premature form of APP is unable to 
be correctly transported to the cell surface and thus trapped 
inside the cell, or upon reaching the cell surface the ablation 
of these sites increases the processing of APP from the cell 
surface. To address this question, the level of the soluble 
APP (sAPP) was measured in the media (Fig. 1d). Both total 
sAPP and sAPP cleaved through the amyloidogenic pathway 
(to produce sAPPβ) were measured by Western. Compared 
to cells expressing only endogenous APP, overexpression 
of  APPWT increased sAPP production that paralleled the 
rise in total cellular APP levels (Fig. 1b). As sAPPβ levels 
 Neurochemical Research
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Fig. 1  Single point mutations in APP that ablate ectodomain N-gly-
cosylation and phosphorylation sites in APP alter its cellular location 
and proteolytic processing. N2a cells were stably transfected with 
wild-type APP (WT) or APP carrying a mutation in a known site of 
phosphorylation (S206A) or N-glycosylation (N467K and N496K). 
a An amino acid schematic showing the domains and relevant PTM 
sites of  APP695. The ferroportin binding region is located inside 
the E2 domain (amino acids 327–348) [6]. Within the ectodomain 
the phosphorylation site (206) is located in the acidic domain and 
the two N-linked glycosylation sites (467 and 496) are located just 
before and after the end of the E2 domain. Numbering is based on the 
amino acid sequence of the 695 amino acid isoform that is prevalent 
in neurons. From the three most common isoforms of APP, the 695 
amino acid form lacks the Kunitz protease inhibitor (KPI) and OX-2 
antigen domain, whereas a 751 only possesses only the KPI domain 
and a 770 isoform contains both domains. b Changes in total cellu-
lar wild-type APP levels were quantified by Western blotting using 
an antibody that recognised the N-terminal (22C11). c Changes in 
trafficking of APP to the cell surface caused by the insertion of each 
mutation was evaluated by flow cytometric quantification of APP on 
the cell surface of non-permeabilised cells. A shift to the left in the 
representative histograms towards the empty vector (EV) control cells 
indicates a reduction in APP detection on the cell surface as quanti-
fied in the graph. d Secreted soluble APP (sAPP) levels in the media 
from which each cell line had been incubated with for 24 h was also 
quantified by Western blotting using the same N-terminal APP anti-
body as in (b) to monitor total sAPP and an antibody that specifically 
recognizes amyloidogenically processed APP (sAPPβ; 1A9). Data 
are means ± SEM, n = 3 for experiments performed on three separate 
occasions, ***p < 0.001 compared to cells transfected with empty 




were fourfold higher than in the endogenously expressing 
cell line, changes to total sAPP in this cell type were likely 
to predominantly come from amyloidogenic processing 
of APP. In contrast to the  APPWT cell line, deletion of the 
phosphorylation  (APPS206A) or N-glycosylation  (APPN467K 
and  APPN496K) sites caused a significant decrease in total 
sAPP compared to either the  APPWT or parental (Hyg) cell 
line. Despite this reduction of total levels of sAPP, when 
compared to the empty vector control only the N-glycosyla-
tion deletion mutants had reduced sAPPβ levels whereas 
 APPS206A was still partially increased. The secretion of APP 
being impaired by the deletion of these post translational 
sites infer that the lack of cell surface APP is likely to be 
caused by these mutations impairing APP trafficking to the 
cell surface.
APP Mutants Alter Cellular Iron Processing Causing 
Retention of Iron
A proposed function of APP is to facilitate iron efflux by 
stabilising FPN on the cell surface [6–8]. Upon confirmation 
that deletion of extracellular phosphorylation  (APPS206A) 
or N-glycosylation  (APPN467K and  APPN496K) sites in APP 
modified its transport to the cell surface (Fig. 1), we inves-
tigated whether these changes had consequential effects on 
iron homeostasis. Comparable to cell surface APP levels 
upon overexpression of  APPWT (Fig. 1c), FPN was found to 
be substantially elevated in these cells (Fig. 2). The cell sur-
face presence of FPN in cells expressing the phosphorylation 
or N-glycosylation mutations also correlated with surface 
APP levels, whereby these mutations reduced the FPN levels 
compared to  APPWT, despite these still being higher than the 
empty vector control.
Cells were treated with iron (50 µM; 24 h) to determine if 
these mutations in APP altered the ability to regulate cellular 
iron levels due to an impaired capacity in stabilising FPN on 
the cell surface. Iron levels in the stable overexpressing cell 
lines after iron treatment were compared by directly measur-
ing the chelatable labile iron pool (LIP) levels (Fig. 3a) and 
indirectly via expression of ferritin; an iron response protein 
(Fig. 3b). Both types of analysis confirmed that cells stably 
expressing the post translational mutants had an increase 
Fig. 2  The effect of ectodomain N-glycosylation and phosphorylation 
site mutations in APP on stabilizing cell surface ferroportin. The role 
of APP in iron homeostasis is proposed to be through an ability to 
retain ferroportin (FPN) on the cell surface for iron efflux. a Repre-
sentative histograms of flow cytometry measurements for cell surface 
FPN indicate a peak shift to the left in cell lines carrying APP muta-
tions in a phosphorylation (S206A) or N-glycosylation (N467K and 
N496K) site compared to  APPWT overexpressing cell lines. b Quanti-
fication of the % change in FPN on the cell surface show that all APP 
overexpressing cell lines have elevated detectable FPN compared to 
the empty vector control line that only contains endogenous APP, but 
that FPN expression in cell lines with APP PTMs are significantly 
lower than  APPWT. Data are means ± SEM, n = 3 for three separate 
experiments, ***p < 0.001 compared to cells transfected with empty 
vector and ###p < 0.001 compared to  APPWT cells. All were analyzed 
by two-tailed t tests
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in cellular iron compared to cells overexpressing  APPWT 
(Fig. 3). Comparative iron relevant readouts to non-over-
expressing cell lines were not analysed due to disparities 
between cells chronically expressing empty vector or  APPWT 
in a high iron environment. An elevated intracellular iron 
level in  APPWT cells compared to control (Hyg) (data in 
Fig. 3b not quantified) was considered to be a consequence 
of the  APPWT cell line having to adapt to survival under high 
iron efflux. However, this observation should not detract 
from the results that illustrate that the inhibition of a PTM 
to APP that is known to impair cell surface location of APP 
and FPN, can increase intracellular iron levels.
Discussion
In a neuroblastoma model stably overexpressing APP, we 
provide support that PTMs are required for the trafficking 
of APP to the neuronal surface and further consolidate a 
proposed life cycle for APP. Mutations in the ectodomain 
of APP that ablate the correct N-glycosylation or phospho-
rylation of the protein lead to a retention of intracellular 
APP whilst also reducing the cell surface presence and sub-
sequent secretion of APP. These observations illustrate a 
necessity in these PTMs to regulate the trafficking of APP to 
the cell surface and indicate how mature protein assembly by 
these modifications are a pre-requisite to proteolytic cleav-
age through either the non-amyloidogenic or amyloidogenic 
pathways. However, whilst there was a strong decrease to the 
surface location of APP in cells carrying these mutations it 
was also noted that levels of surface APP were still higher 
than the endogenously expressing parental line, indicating 
that trafficking had not been completely ablated but rather 
slowed. Similar observations have been previously observed 
[19] in which both impaired glycosylation and phospho-
rylation of APP were proven to result in the retardation of 
membrane trafficking rather than a reduction in surface APP 
half-life [25, 26]. N-glycosylation and ectodomain phospho-
rylation occur in discrete cellular compartments before it 
is trafficked to the cell surface. While we did not directly 
illustrate where APP accumulated within our cell model, 
prior evidence in non-neuronal cell lines strongly support 
mutations that impair N-glycosylation at these sites causing 
a retention of APP in the ER [15, 18–20] and mutations in 
ectodomain phosphorylation sites leading to accumulation 
in the TGN [21]. Of most relevance to this study, these prior 
reports agree that cell surface presence of APP is disrupted 
when these sites are mutated.
To date, the regulatory role of these PTMs on the func-
tion of full length APP has not been investigated. Instead, 
a greater focus has been on how these modifications effect 
downstream mechanisms such as the propensity to alter 
proteolytic processing and the production of cleavage prod-
ucts such as Aβ. Therefore, to our knowledge this is the first 
investigation into how these modifications regulate a known 
functional role of APP; the regulation of intracellular iron 
homeostasis. FPN is the only known iron export pore protein 
and must be localised on the cell surface for iron efflux to 
take place. APP is translationally regulated through an iron 
responsive element site in its promoter [27] and cell sur-
face APP is increased in response to high intracellular iron 
[8]. Whilst FPN-dependent iron efflux can be modulated by 
several proteins (e.g. ceruloplasmin [28]), the absence of 
total APP in select cells including neurons has previously 
Fig. 3  The effect of ectodomain N-glycosylation and phosphorylation 
site mutations in APP on intracellular iron homeostasis. a To directly 
measure the labile pool of intracellular iron a modified Calcein-AM 
assay quantified chelatable iron from cell lines containing post trans-
lational mutations compared to  APPWT. All point mutations in APP 
caused a significant increase in iron within the cell. b Western blot-
ting was used to quantify changes in expression of the iron responsive 
protein ferritin (FT) to indirectly confirm the altered iron homeosta-
sis in each cell line observed in (a). Data are means ± SEM, n = 3 for 
three separate experiments, ###p < 0.001 compared to  APPWT cells. 
All were analyzed by two-tailed t tests
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been shown to reduce levels of FPN on the cell surface [8] 
subsequently leading to intracellular iron retention [6, 7, 
29]. However, it was unknown until now whether impaired 
maturation of APP would also have a consequential effect 
on cell surface FPN levels and regulation of intracellular 
iron. Outcomes from this study illustrate that disruption in 
the levels of APP on the cell surface caused by these post-
translational mutations correlate with a reduction in surface 
FPN. This reduced capability to efflux cellular iron leads 
to an iron retention phenotype in these mutants compared 
to cells overexpressing wild-type APP. Despite total APP 
levels being increased in the APP mutant cell lines, the data 
underscores the importance of correct cellular trafficking 
for a functional role of APP on the cell surface. The iron 
retention caused by a permanent alteration in APP trafficking 
within these cell lines also highlight a possible mechanism 
by which the cell could modulate iron homeostasis through 
post-translational changes to APP.
The initial approach in the selection of which PTMs to 
study was based on whether these mutations would have a 
dual role in the protein; primarily in regulating the traffick-
ing of APP to the cell surface and secondly if proximity of 
these sites to the FPN binding region in APP [6, 7, 29] were 
essential for stabilizing FPN on the cell surface. Outcomes 
have predominantly illustrated that these PTMs are essential 
for the correct location of APP for its functional role and 
therefore it is difficult to establish whether these sites are 
also required for FPN binding. However, it is worth not-
ing that even if these PTMs were required for FPN binding 
their absence would be of little relevance if APP is primarily 
unable to be trafficked to the site of interaction on the cell 
surface.
This study cements an importance of APP trafficking in 
iron processing and indicates a regulatory nexus in cellular 
iron metabolism. Promising provisional outcomes provided 
here support further interrogation of the other PTMs known 
to occur with APP. This would provide greater clarity on 
the post-translational regulation of APP in iron efflux and 
whether interplay between the different types of modifi-
cation can occur. Of relevance, APP is phosphorylated at 
several sites and whilst this study focused on only the ecto-
domain site at S206, this only accounts for 15% of APP ecto-
domain phosphorylation with S198 phosphorylation being a 
preceding factor [21] and heparin binding causing inhibition 
[22]. This points to a dynamic and transient interrelationship 
between all of the PTMs of APP to which this study has only 
just begun to scratch the surface.
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